Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Delayed NSE India S.E. Other stock markets 11:46:25 2024-09-19 pm EDT			5-day change	1st Jan Change
3,283.40 ^INR	+0.26%		-2.23%	+28.26%

Aug. 12	Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,720 From INR2,713, Keeps at Buy	MT
Aug. 08	Dr. Lal PathLabs' Consolidated Net Profit Shows Growth in Fiscal Q1	MT

Presentation Operator MessageOperator (Operator)Ladies and gentlemen, good day, and welcome to...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Dr. Lal PathLabs Limited

Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,720 From INR2,713, Keeps at Buy	Aug. 12	MT
Dr. Lal PathLabs' Consolidated Net Profit Shows Growth in Fiscal Q1	Aug. 08	MT
Dr. Lal PathLabs Limited, Q1 2025 Earnings Call, Aug 07, 2024	Aug. 07
India's Dr Lal PathLabs tops Q1 profit estimates on strong testing demand	Aug. 07	RE
Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25	Aug. 07	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 07	CI
Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024	Jun. 29	CI
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	May. 14	MT
Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6%	May. 13	MT
Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024	May. 10
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand	May. 10	RE
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	May. 10	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 10	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	Apr. 26	CI
Dr Lal Pathlabs Names CEO	Mar. 17	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	Mar. 16	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	Mar. 03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	Feb. 05	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	Feb. 01	MT
Dr. Lal PathLabs Seeks M&A	Feb. 01	CI
Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	Feb. 01
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	Feb. 01	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	Feb. 01	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 01	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	Jan. 25	MT